ADA 2025: Novo Nordisk highlights strong portfolio data with new semaglutide and CagriSema results, redefining possibilities in obesity and diabetes care

Bagsværd, Denmark, 10 June – Novo Nordisk today announced that new data from its industry-leading portfolio in metabolic and cardiovascular health will be showcased at the upcoming American Diabetes Association (ADA) 85 Scientific Sessions taking place in Chicago US, 20 – 23 June 2025. A total of 29 abstracts will be presented, including trials investigating the weight loss efficacy of higher dose Wegovy (semaglutide 7.2 mg) in people with obesity (STEP UP) and those with obesity and type 2 diabetes (STEP U ...